François Philippon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3359006/publications.pdf

Version: 2024-02-01

44 papers 2,007 citations

471509 17 h-index 42 g-index

44 all docs

44 docs citations

times ranked

44

2600 citing authors

#	Article	IF	CITATIONS
1	Conduction Disturbances After Transcatheter Aortic Valve Replacement. Circulation, 2017, 136, 1049-1069.	1.6	386
2	Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. New England Journal of Medicine, 2019, 380, 1895-1905.	27.0	251
3	Impact of New-Onset Left Bundle Branch Block and Periprocedural Permanent Pacemaker Implantation on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2016, 9, e003635.	3.9	234
4	Subclinical Atrial Fibrillation in Older Patients. Circulation, 2017, 136, 1276-1283.	1.6	194
5	Prevention of Arrhythmia Device Infection Trial. Journal of the American College of Cardiology, 2018, 72, 3098-3109.	2.8	160
6	Arrhythmic Burden as Determined by Ambulatory Continuous Cardiac Monitoring in Patients With New-Onset Persistent Left Bundle Branch Block Following Transcatheter Aortic ValveÂReplacement. JACC: Cardiovascular Interventions, 2018, 11, 1495-1505.	2.9	112
7	Risk Factors for Infections Involving Cardiac Implanted Electronic Devices. Journal of the American College of Cardiology, 2019, 74, 2845-2854.	2.8	94
8	Arrhythmia Burden in Elderly Patients With Severe Aortic Stenosis as Determined by Continuous Electrocardiographic Recording. Circulation, 2015, 131, 469-477.	1.6	86
9	Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 Implantable Cardioverter-Defibrillator Guidelines. Canadian Journal of Cardiology, 2017, 33, 174-188.	1.7	84
10	Randomized Cluster Crossover Trials for Reliable, Efficient, Comparative Effectiveness Testing: Design of the Prevention of Arrhythmia Device Infection Trial (PADIT). Canadian Journal of Cardiology, 2013, 29, 652-658.	1.7	54
11	Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair System for the Treatment of SevereÂTricuspid Regurgitation. JACC: Cardiovascular Interventions, 2019, 12, 1438-1447.	2.9	44
12	Impact of Massive or Torrential Tricuspid Regurgitation in Patients Undergoing Transcatheter Tricuspid Valve Intervention. JACC: Cardiovascular Interventions, 2020, 13, 1999-2009.	2.9	42
13	Incidence, Predictors, and Procedural Results of Upgrade to Resynchronization Therapy. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 152-158.	4.8	29
14	Impact of Preexisting Left Bundle Branch Block in Transcatheter Aortic Valve Replacement Recipients. Circulation: Cardiovascular Interventions, 2018, 11, e006927.	3.9	26
15	Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension. Circulation: Cardiovascular Interventions, 2021, 14, e009685.	3.9	26
16	Use of healthcare claims to validate the Prevention of Arrhythmia Device Infection Trial cardiac implantable electronic device infection risk score. Europace, 2021, 23, 1446-1455.	1.7	23
17	Role of radionuclide imaging for diagnosis of device and prosthetic valve infections. World Journal of Cardiology, 2016, 8, 534.	1.5	20
18	Rationale and design of the randomized prospective ATLAS study: Avoid Transvenous Leads in Appropriate Subjects. American Heart Journal, 2019, 207, 1-9.	2.7	19

#	Article	IF	CITATIONS
19	Ambulatory Electrocardiographic Monitoring Following Minimalist Transcatheter AorticÂValveÂReplacement. JACC: Cardiovascular Interventions, 2021, 14, 2711-2722.	2.9	15
20	Findings of remote monitoring of implantable cardioverter defibrillators during the COVIDâ€19 pandemic. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 1366-1372.	1.2	12
21	Impact of Cardiac Resynchronization Therapy on Hospitalizations in the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial. Circulation, 2014, 129, 2021-2030.	1.6	10
22	Arrhythmic burden in patients with new-onset persistent left bundle branch block after transcatheter aortic valve replacement: 2-year results of the MARE study. Europace, 2021, 23, 254-263.	1.7	10
23	Management of Implantable Cardioverter Defibrillator Recipients: Care Beyond Guidelines. Canadian Journal of Cardiology, 2017, 33, 977-990.	1.7	8
24	Heart failure following transcatheter aortic valve replacement. Expert Review of Cardiovascular Therapy, 2021, 19, 695-709.	1.5	8
25	Remote-only monitoring for patients with cardiac implantable electronic devices: a before-and-after pilot study. CMAJ Open, 2021, 9, E53-E61.	2.4	7
26	Ten Questions Cardiologists Should Be Able to Answer About Cardiac Sarcoidosis: Case-Based Approach and Contemporary Review. CJC Open, 2021, 3, 532-548.	1.5	7
27	Arrhythmic Risk Following Recovery of Left Ventricular Ejection Fraction in Patients with Primary Prevention ICD. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 680-689.	1.2	6
28	Driving Restrictions and Early Arrhythmias in Patients Receiving a Primary-Prevention Implantable Cardioverter-Defibrillator (DREAM-ICD) Study. Canadian Journal of Cardiology, 2020, 36, 1269-1277.	1.7	5
29	Canadian Registry of Implantable Electronic Device Outcomes: Longer-term follow-up of the Riata lead under advisory. Heart Rhythm, 2018, 15, 524-529.	0.7	4
30	Ventricular Arrhythmia in Septal and Apical Hypertrophic Cardiomyopathy: The French-Canadian Experience. Frontiers in Cardiovascular Medicine, 2020, 7, 548564.	2.4	4
31	Transcatheter Tricuspid Valve Intervention in Patients With Previous Left Valve Surgery. Canadian Journal of Cardiology, 2021, 37, 1094-1102.	1.7	4
32	Late arrhythmias in patients with new-onset persistent left bundle branch block after transcatheter aortic valve replacement using a balloon-expandable valve. Heart Rhythm, 2021, 18, 1733-1740.	0.7	4
33	Impact of Choice of Prophylaxis on the Microbiology of Cardiac Implantable Electronic Device Infections: Insights From the Prevention of Arrhythmia Device Infection Trial (PADIT). Open Forum Infectious Diseases, 2021, 8, ofab513.	0.9	4
34	Understanding, Predicting, Preventing, and Treating Ventricular Arrhythmias: Pushing Sudden Death Into Overtime. Canadian Journal of Cardiology, 2022, 38, 414-417.	1.7	3
35	Usefulness of cardiac resynchronization therapy in the recovery of patients with left ventricular assist devices. International Journal of Cardiology, 2016, 223, 297-298.	1.7	2
36	Canadian Registry of Implantable Electronic Device Outcomes: Surveillance of High-Voltage Leads. Canadian Journal of Cardiology, 2018, 34, 808-811.	1.7	2

#	Article	lF	CITATIONS
37	SCN5A â€C683R exhibits combined gainâ€ofâ€function and lossâ€ofâ€function properties related to adrenalineâ€triggered ventricular arrhythmia. Experimental Physiology, 2021, 106, 683-699.	2.0	2
38	Canadian Registry of Electronic Device Outcomes: remote monitoring outcomes in the Abbott battery performance alertâ€"a multicentre cohort. Europace, 2021, 23, 1319-1323.	1.7	2
39	Anomalous Left Coronary Artery From the Pulmonary Artery: Masquerading as Peripartum Cardiomyopathy. Annals of Thoracic Surgery, 2018, 106, e33-e35.	1.3	1
40	Role of Continuous ECG Monitoring to Improve Management of Conduction Disturbances Post-Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e008674.	3.9	1
41	Twiddler Syndrome without Lead Dislodgment Discovered by Remote Monitoring. Case Reports in Cardiology, 2021, 2021, 1-4.	0.2	1
42	Evolution of Devices to Prevent Sudden Cardiac Death: Contemporary Clinical Impacts. Canadian Journal of Cardiology, 2022, , .	1.7	1
43	Very Late Continued Reverse Remodelling After Cardiac Resynchronization Therapy in Patients With Extreme Left Ventricular Dilatation. Canadian Journal of Cardiology, 2017, 33, 831.e1-831.e3.	1.7	0
44	Understanding important factors for arrhythmogenicity associated with transcatheter aortic valve implantation including left bundle branch block: Authors' reply. Europace, 2021, 23, 323-324.	1.7	0